Edwards Lifesciences (NYSE: EW) reported earnings on July 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Edwards Lifesciences missed slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew significantly.

Margins increased across the board.

Revenue details
Edwards Lifesciences logged revenue of $482.0 million. The 19 analysts polled by S&P Capital IQ foresaw revenue of $489.6 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $431.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.67. The 22 earnings estimates compiled by S&P Capital IQ predicted $0.65 per share. GAAP EPS of $0.57 for Q2 were 19% higher than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 73.1%, 270 basis points better than the prior-year quarter. Operating margin was 19.9%, 240 basis points better than the prior-year quarter. Net margin was 14.1%, 60 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $483.4 million. On the bottom line, the average EPS estimate is $0.65.

Next year's average estimate for revenue is $1.95 billion. The average EPS estimate is $2.66.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 142 members out of 197 rating the stock outperform, and 55 members rating it underperform. Among 64 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Edwards Lifesciences a green thumbs-up, and 22 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $97.11.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.